Clarithromycin as an Immunomodulator in Urosepsis
Author Information
Author(s): Giamarellos-Bourboulis Evangelos J, Antonopoulou Anastasia, Raftogiannis Maria, Koutoukas Pantelis, Tsaganos Thomas, Tziortzioti Vassiliki, Panagou Charalambos, Adamis Theodoros, Giamarellou Helen
Primary Institution: 4th Department of Internal Medicine, University of Athens, Medical School, Greece
Hypothesis
Can clarithromycin improve survival in experimental urosepsis caused by multidrug-resistant Pseudomonas aeruginosa when administered late?
Conclusion
Clarithromycin administered late in experimental urosepsis by multidrug-resistant P. aeruginosa prolonged survival and improved clinical outcomes.
Supporting Evidence
- Clarithromycin improved survival rates in treated rabbits compared to controls.
- The combination of clarithromycin and amikacin showed a significant survival advantage.
- Clarithromycin reduced total oxidant status in treated animals.
Takeaway
Clarithromycin can help sick rabbits live longer when they have a serious infection, even if it's given after the infection starts.
Methodology
40 rabbits were divided into four groups and treated with clarithromycin, amikacin, both, or saline after inducing urosepsis.
Limitations
The study was conducted on rabbits, which may not fully represent human responses.
Participant Demographics
40 white New Zealand male rabbits, mean weight 3.19 kg.
Statistical Information
P-Value
0.049
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website